Sirona Biochem Co.

Dentsply Sirona has appointed Donald Zurbay to the board of directors effective Jan. 10; he will serve on the audit and finance committee. Zurbay was previously president and CEO of Patterson Companies and brings extensive experience in the dental industry as well as prior CFO experience at St. Jude Medical. The board will expand from ten to eleven members, and the company is also establishing a Growth and Value Creation Committee to oversee the return-to-growth action plan. » Más en de.investing.com

Dentsply Sirona announced that Richard C. Rosenzweig will relinquish his role as executive vice president for corporate development, general counsel and secretary by mutual agreement and will serve as a special legal advisor through March 4, 2026, for $30,000 per month. Rosenzweig will receive severance and other contractually guaranteed benefits, and will then serve one year as an independent consultant at $20,000 per month; payments are conditioned on a release and compliance with post‑employment obligations. The change comes amid short‑term profitability pressures while Dentsply Sirona makes operational personnel moves (appointment of Aldo M. Denti, retention bonus for Tony Johnson) and analysts reported slightly lowered price targets. » Más en de.investing.com

At the Baird Global Healthcare Conference, Dentsply Sirona announced strategic measures to revive the business, including higher R&D spending (target: 7% of revenue), reallocation of resources and increased sales investments. The company is targeting an operating margin above 19% and a reduction of SG&A to about 30% of revenue, as well as EPS growth of 8–10%, driven mainly by share buybacks. Other measures include ERP implementations, SKU rationalization and retaining the Wellspect business, which contributes roughly 40% of free cash flow. Regional focus is on growth in the US and EMEA and on increasing free cash flow to improve shareholder returns. » Más en de.investing.com

At the Morgan Stanley Global Healthcare Conference, Dentsply Sirona under CEO Dan Scavilla outlined a realignment focused on faster decision-making, higher operational efficiency and reallocating resources to R&D and sales. For 2025 the company expects an organic revenue decline of 2–4%, a margin target above 19% and targeted annual free cash flow of $300–400 million. It cited excess working capital of more than $1 billion, tariff-related burdens of around $80 million and ERP and inventory challenges. Long term, Dentsply Sirona plans deeper U.S. market penetration, increased R&D spending (≥7% of revenue), potential bolt-on acquisitions and a reviewed EPS target for 2026. » Más en de.investing.com

If you had invested $10,000 in DENTSPLY SIRONA shares ten years ago (closing price then $53.26), you would now hold 187.758 shares and the investment would be worth only $2,692.45 at a closing price of $14.34, a decline of 73.08 percent. The calculation does not take stock splits or dividends into account; DENTSPLY SIRONA's market capitalization was most recently quoted at $2.87 billion. » Más en finanzen.net